Clinicoprognostical features of endometrial cancer patients with somatic mtDNA mutations

Andrzej Semczuk, Anna Lorenc, Lechoslaw Putowski, Konrad Futyma, Jaroslaw Bryk, Pawel Miotla, Ewa Bartnik

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Somatic mitochondrial DNA (mtDNA) mutations have been found in a subset of endometrial cancers (EC) from different populations. We have investigated the relationship between mtDNA changes and clinical and pathological variables of women affected by EC. mtDNA mutations were detected both in early (3/32; 9%) and in advanced (1/8; 12%) stages of uterine tumors. However, patients carrying the mtDNA mutations or the normal mtDNA sequence had indistinguishable clinicopathological data, including age, clinical stage, histological grade and type or depth of myometrial invasion. It is noteworthy that mtDNA mutations were not detected in hyperplastic endometrial tissues or in ECs coexisting with hyperplasia, nor in a single case of endometrial stromal sarcoma. LOH at the tumor suppressor genes RB1 and TP53 as well as p16INK4A alterations (LOH, gene deletion) were found in tumors carrying mtDNA mutations. These results suggest that somatic mtDNA mutations are detected in a subset of ECs, although they are unrelated to clinicopathological variables of cancer.

Original languageEnglish
Pages (from-to)1041-1045
Number of pages5
JournalOncology Reports
Volume16
Issue number5
DOIs
Publication statusPublished - Nov 2006
Externally publishedYes

Fingerprint

Endometrial Neoplasms
Mitochondrial DNA
Mutation
Endometrial Stromal Sarcoma
Neoplasms
Gene Deletion
Tumor Suppressor Genes
Hyperplasia
Population

Cite this

Semczuk, A., Lorenc, A., Putowski, L., Futyma, K., Bryk, J., Miotla, P., & Bartnik, E. (2006). Clinicoprognostical features of endometrial cancer patients with somatic mtDNA mutations. Oncology Reports, 16(5), 1041-1045. https://doi.org/10.3892/or.16.5.1041
Semczuk, Andrzej ; Lorenc, Anna ; Putowski, Lechoslaw ; Futyma, Konrad ; Bryk, Jaroslaw ; Miotla, Pawel ; Bartnik, Ewa. / Clinicoprognostical features of endometrial cancer patients with somatic mtDNA mutations. In: Oncology Reports. 2006 ; Vol. 16, No. 5. pp. 1041-1045.
@article{0cdcba88caea49338bb3e49470ecb684,
title = "Clinicoprognostical features of endometrial cancer patients with somatic mtDNA mutations",
abstract = "Somatic mitochondrial DNA (mtDNA) mutations have been found in a subset of endometrial cancers (EC) from different populations. We have investigated the relationship between mtDNA changes and clinical and pathological variables of women affected by EC. mtDNA mutations were detected both in early (3/32; 9{\%}) and in advanced (1/8; 12{\%}) stages of uterine tumors. However, patients carrying the mtDNA mutations or the normal mtDNA sequence had indistinguishable clinicopathological data, including age, clinical stage, histological grade and type or depth of myometrial invasion. It is noteworthy that mtDNA mutations were not detected in hyperplastic endometrial tissues or in ECs coexisting with hyperplasia, nor in a single case of endometrial stromal sarcoma. LOH at the tumor suppressor genes RB1 and TP53 as well as p16INK4A alterations (LOH, gene deletion) were found in tumors carrying mtDNA mutations. These results suggest that somatic mtDNA mutations are detected in a subset of ECs, although they are unrelated to clinicopathological variables of cancer.",
keywords = "Endometrial cancer, Endometrial hyperplasia, Mitochondrial DNA, Mutations",
author = "Andrzej Semczuk and Anna Lorenc and Lechoslaw Putowski and Konrad Futyma and Jaroslaw Bryk and Pawel Miotla and Ewa Bartnik",
year = "2006",
month = "11",
doi = "10.3892/or.16.5.1041",
language = "English",
volume = "16",
pages = "1041--1045",
journal = "Oncology Reports",
issn = "1021-335X",
publisher = "Spandidos Publications",
number = "5",

}

Semczuk, A, Lorenc, A, Putowski, L, Futyma, K, Bryk, J, Miotla, P & Bartnik, E 2006, 'Clinicoprognostical features of endometrial cancer patients with somatic mtDNA mutations', Oncology Reports, vol. 16, no. 5, pp. 1041-1045. https://doi.org/10.3892/or.16.5.1041

Clinicoprognostical features of endometrial cancer patients with somatic mtDNA mutations. / Semczuk, Andrzej; Lorenc, Anna; Putowski, Lechoslaw; Futyma, Konrad; Bryk, Jaroslaw; Miotla, Pawel; Bartnik, Ewa.

In: Oncology Reports, Vol. 16, No. 5, 11.2006, p. 1041-1045.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Clinicoprognostical features of endometrial cancer patients with somatic mtDNA mutations

AU - Semczuk, Andrzej

AU - Lorenc, Anna

AU - Putowski, Lechoslaw

AU - Futyma, Konrad

AU - Bryk, Jaroslaw

AU - Miotla, Pawel

AU - Bartnik, Ewa

PY - 2006/11

Y1 - 2006/11

N2 - Somatic mitochondrial DNA (mtDNA) mutations have been found in a subset of endometrial cancers (EC) from different populations. We have investigated the relationship between mtDNA changes and clinical and pathological variables of women affected by EC. mtDNA mutations were detected both in early (3/32; 9%) and in advanced (1/8; 12%) stages of uterine tumors. However, patients carrying the mtDNA mutations or the normal mtDNA sequence had indistinguishable clinicopathological data, including age, clinical stage, histological grade and type or depth of myometrial invasion. It is noteworthy that mtDNA mutations were not detected in hyperplastic endometrial tissues or in ECs coexisting with hyperplasia, nor in a single case of endometrial stromal sarcoma. LOH at the tumor suppressor genes RB1 and TP53 as well as p16INK4A alterations (LOH, gene deletion) were found in tumors carrying mtDNA mutations. These results suggest that somatic mtDNA mutations are detected in a subset of ECs, although they are unrelated to clinicopathological variables of cancer.

AB - Somatic mitochondrial DNA (mtDNA) mutations have been found in a subset of endometrial cancers (EC) from different populations. We have investigated the relationship between mtDNA changes and clinical and pathological variables of women affected by EC. mtDNA mutations were detected both in early (3/32; 9%) and in advanced (1/8; 12%) stages of uterine tumors. However, patients carrying the mtDNA mutations or the normal mtDNA sequence had indistinguishable clinicopathological data, including age, clinical stage, histological grade and type or depth of myometrial invasion. It is noteworthy that mtDNA mutations were not detected in hyperplastic endometrial tissues or in ECs coexisting with hyperplasia, nor in a single case of endometrial stromal sarcoma. LOH at the tumor suppressor genes RB1 and TP53 as well as p16INK4A alterations (LOH, gene deletion) were found in tumors carrying mtDNA mutations. These results suggest that somatic mtDNA mutations are detected in a subset of ECs, although they are unrelated to clinicopathological variables of cancer.

KW - Endometrial cancer

KW - Endometrial hyperplasia

KW - Mitochondrial DNA

KW - Mutations

UR - http://www.scopus.com/inward/record.url?scp=39049178352&partnerID=8YFLogxK

UR - https://www.spandidos-publications.com/or

U2 - 10.3892/or.16.5.1041

DO - 10.3892/or.16.5.1041

M3 - Article

VL - 16

SP - 1041

EP - 1045

JO - Oncology Reports

JF - Oncology Reports

SN - 1021-335X

IS - 5

ER -